Table 4 Serology-clinical associations of anti-CENP antibodies in SLE
From: Clinical and serological evaluation of a novel CENP-A peptide based ELISA
Patient ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | CENP pos CENP-A pos CENP-B pos | SLE cohort (n = 105) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
CENP-A/CENP-B [RU] | 0.3/3.4 | 1.3/1.6 | 1.2/1.8 | 5.2/6.3 | 1.5/1.3 | 1.5/2.4 | 1.5/0.7 | 0.8/1.5 | 8/8 (100.0%) | 8/105 (7.6%) | |
CENP-A | neg | neg | neg | pos | pos | pos | pos | neg | 4/8 (50.0%) | 4/105 (3.8%) | |
CENP-B | pos | pos | pos | pos | neg | pos | neg | pos | 6/8 (75.0%) | 6/105 (5.7% | |
SLEDAI-2K | 6 | 2 | 2 | 28 | 11 | 2 | 16 | na | 6 | 8 | |
Renal involvement | type V | no | yes* | type IV | type II | type V | no | type V | 6/8 (75.0%) 3/4 (75.0%) 5/6 (83.3%) | 70/105 (66.6%) | ns |
Skin involvement | yes | no | no | no | no | no | yes | yes | 3/8 (37.5%) 1/4 (25.0%) 2/6 (33.3%) | 69/105 (65.7%) | ns |
CNS involvement | no | no | no | no | no | no | no | yes | 1/8 (12.5%) 0/4 (0.0%) 1/6 (16.7%) | 13/105 (12.4%) | ns |
Specific joint involvement (Jaccoud arthritis or deformity) | no | yes | yes | no | no | no | no | yes | 3/8 (37.5%) 0/4 (0.0%) 3/6 (50.0%) | 3/105 (2.9%) | p = 0.0006 ns p = 0.0002 |
Lung/heart involvement | no | no | yes | yes | no | no | yes | no | 3/8 (37.5%) 2/4 (50.0%) 2/6 (33.3%) | 37/105 (35.2%) | ns |
Liver involvement | yes | no | no | no | no | no | no | yes | 2/8 (25.0%) 0/4 (0.0%) 2/6 (33.3%) | 4/105 (3.8%) | p = 0.0568 ns p = 0.0313 |
Anti-phospholipid syndrome | yes | yes | yes | yes | yes | yes | no | no | 6/8 (75.0%) 3/4 (75.0%) 5/6 (83.3%) | 31/105 (29.5%) | p = 0.0157 p = 0.1523 p = 0.0165 |
Raynaud's Syndrome | yes | no | no | no | no | yes | yes | yes | 4/8 (50.0%) 2/4 (50.0%) 3/6 (50.0%) | 54/105 (51.4%) | ns |